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ABSTRACT Double-stranded RNAs (dsRNA) produced during human cytomegalovirus
(HCMV) infection activate the antiviral kinase protein kinase R (PKR), which potently
inhibits virus replication. The HCMV pTRS1 and pIRS1 proteins antagonize PKR to
promote HCMV protein synthesis and replication; however, the mechanism by which
pTRS1 inhibits PKR is unclear. PKR activation occurs in a three-step cascade. First,
binding to dsRNA triggers PKR homodimerizaton. PKR dimers then autophosphoryl-
ate, leading to a conformational shift that exposes the binding site for the PKR sub-
strate eIF2. Consistent with previous in vitro studies, we found that pTRS1 bound
and inhibited PKR. pTRS1 binding to PKR was not mediated by an RNA intermediate,
and mutations in the pTRS1 RNA binding domain did not affect PKR binding or inhi-
bition. Rather, mutations that disrupted the pTRS1 interaction with PKR ablated the
ability of pTRS1 to antagonize PKR activation by dsRNA. pTRS1 did not block PKR
dimerization and could bind and inhibit a constitutively dimerized PKR kinase do-
main. In addition, pTRS1 binding to PKR inhibited PKR kinase activity. Single amino
acid point mutations in the conserved eIF2 binding domain of PKR disrupted
pTRS1 binding and rendered PKR resistant to inhibition by pTRS1. Consistent with a
critical role for the conserved eIF2 contact site in PKR binding, pTRS1 bound an ad-
ditional eIF2 kinase, heme-regulated inhibitor (HRI), and inhibited eIF2 phosphor-
ylation in response to an HRI agonist. Together our data suggest that pTRS1 inhibits
PKR by binding to conserved amino acids in the PKR eIF2 binding site and block-
ing PKR kinase activity.
IMPORTANCE The antiviral kinase PKR plays a critical role in controlling HCMV repli-
cation. This study furthered our understanding of how HCMV evades inhibition by
PKR and identified new strategies for how PKR activity might be restored during in-
fection to limit HCMV disease.
KEYWORDS human herpesvirus, human cytomegalovirus, HCMV, gene expression,
protein synthesis, mRNA translation, eIF2, protein kinase R, PKR, innate immunity
Protein kinase R (PKR) plays a critical role in the cellular intrinsic antiviral response(1). Double-stranded RNAs (dsRNAs) produced during viral infection activate PKR,
leading to phosphorylation of its only known substrate, the  subunit of the eIF2
translation initiation factor (eIF2) (2–4). Phosphorylation of eIF2 reduces formation of
the ternary complex, which is composed of eIF2, GTP, and a charged methionyl tRNA
(tRNAMet) (5). Since the ternary complex is required for translation initiation, activation
of PKR limits the synthesis of both cellular and viral proteins and inhibits virus
replication (6, 7). Active PKR further limits virus replication by increasing type I inter-
feron expression, stimulating apoptosis, inducing autophagy, and possibly activating
inflammasomes (8–14). Together, these functions make PKR a potent antiviral effector
capable of inhibiting the replication of many viruses.
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Both RNA and DNA viruses generate dsRNA ligands that activate PKR during
infection. Structured regions of RNA virus genomes and dsRNA replicative intermedi-
ates are the most likely triggers of PKR activation during RNA virus infection (15–17).
dsRNAs produced by overlapping transcriptional units during DNA virus replication
likely drive PKR activation (18, 19). While PKR exists as an inactive monomer in
uninfected cells, binding to dsRNA, mediated by two amino-terminal dsRNA binding
domains (dsRBDs), results in a conformational shift that allows for PKR dimerization.
Dimerization results in PKR autophosphorylation on multiple serine and threonine
residues; however, only phosphorylation on threonine 446 (Thr446) and 451 (Thr451) in
the PKR kinase domain (KD) activation loop are necessary for PKR activation (16, 20–23).
Following autophosphorylation, conserved residues within the G helix in the C-lobe of
the PKR kinase domain mediate its interaction with eIF2 (3, 4). PKR binding to dsRNA
ligands thus leads to a catalytically active PKR capable of binding and phosphorylating
eIF2, resulting in inhibition of protein synthesis and decreased viral replication.
Almost every virus encodes a PKR inhibitor, underscoring the critical role of PKR in
the antiviral response (1). In several cases a single virus employs multiple proteins to
limit PKR activation or mitigate the effects of eIF2 phosphorylation. For example,
herpes simplex virus (HSV) encodes three proteins that limit PKR activation and eIF2
phosphorylation to facilitate virus replication. The vhs protein degrades viral dsRNAs
that otherwise activate PKR, while the US11 protein binds PKR and prevents PKR-
dependent eIF2 phosphorylation (12, 24). In addition, the ICP34.5 protein recruits the
cellular protein phosphatase 1 (PP1) to dephosphorylate eIF2 and ensure continued
synthesis of viral proteins (25). Similarly, the murine cytomegalovirus (MCMV) m142 and
m143 proteins and the vaccinia virus (VV) K3L and E3L proteins each function to limit
PKR activation (26–33). Other viruses, including orthomyxoviruses, flaviviruses, and
retroviruses, each encode at least one PKR antagonist, highlighting the important role
of PKR antagonism for successful viral replication (15, 17, 34).
Like the above-mentioned viruses, human cytomegalovirus (HCMV) encodes PKR
antagonists that are necessary for virus replication. The HCMV TRS1 and IRS1 proteins
(pTRS1 and pIRS1, respectively) each inhibit PKR activation (7, 35–37). The amino-
terminal two-thirds of both pTRS1 and pIRS1 are conserved and contain a noncanonical
RNA binding domain that competitively inhibits PKR binding to dsRNA ligands in vitro
(38, 39). While the carboxyl-terminal thirds of pTRS1 and pIRS1 differ in sequence, both
proteins contain a C-terminal PKR binding domain and both can inhibit PKR activation
(6, 7, 37). Expression of either pTRS1 or pIRS1 is sufficient to prevent PKR activation
during HCMV infection of human fibroblasts, and viral protein synthesis and HCMV
replication are dramatically reduced in the absence of both proteins (6, 7, 18). pTRS1
and pIRS1 have additional functions, including promoting mRNA translation and
limiting autophagy (40–49). However, the viral replication defect observed in the
absence of both pTRS1 and pIRS1 is largely reversed through inhibition of PKR
expression (6, 7). Though the other functions of pTRS1 and pIRS1 may play important
roles in other cell types, inhibiting PKR activation appears to be the predominant role
for pTRS1 and pIRS1 during HCMV infection of primary human fibroblasts.
While the role of pTRS1 and pIRS1 as PKR antagonists is well established, questions
remain concerning the mechanism by which they inhibit PKR. pTRS1 binds both dsRNA
and PKR, but the relative importance of these two functions for PKR antagonism is
unknown. In this study, we performed a series of molecular biology and biochemical
experiments to further elucidate the molecular mechanism(s) by which pTRS1 prevents
PKR activation. We found that pTRS1 binding to both dsRNA and PKR contributes to
PKR antagonism, although pTRS1 binding to PKR is the predominant mechanism that
mediates PKR inhibition by the full-length TRS1 protein. Our results suggest that pTRS1
does not block PKR dimerization but rather prevents activating autophosphorylation of
PKR dimers. pTRS1 binding to PKR is mediated through interactions with conserved
amino acids in the PKR eIF2 contact site and results in inhibition of PKR kinase activity.
We also found that pTRS1 binds the heme-regulated inhibitor (HRI) kinase and inhibits
eIF2 phosphorylation in response to the HRI agonist arsenite in PKR-deficient cells.
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Together, our results provide further insight into the mechanism of PKR antagonism by
pTRS1.
RESULTS
pTRS1 inhibits PKR activation by dsRNA. We began by examining the ability of
pTRS1 to inhibit PKR activation in transfected cells. Increasing amounts of a synthetic
dsRNA [poly(I·C)] were added to lysates of cells transfected with either a GFP or pTRS1
expression plasmid, and PKR activation was measured by Western blotting. PKR is
activated by autophosphorylation on Thr446 (T446) and Thr451 (T451), although
phosphorylation of T451 is dependent upon T446 phosphorylation (23, 50). We there-
fore used PKR T446 phosphorylation as a marker of PKR activation. Low levels of
phosphorylated PKR were present in the absence of poly(I·C) in cells expressing GFP,
likely due to stress from transfection. Poly(I·C) activated PKR in cells expressing GFP (Fig.
1A). In contrast, the presence of pTRS1 completely suppressed PKR activation, even at
the highest doses of poly(I·C). Thus, pTRS1 is sufficient to prevent PKR activation by
dsRNA in cell culture.
We next examined the regions of pTRS1 necessary for PKR antagonism. In these
experiments, we used a series of plasmids expressing amino- or carboxyl-terminal
truncations of pTRS1, as they have previously been characterized in vitro (37, 39) (Fig.
1B and Table 1) and measured PKR T446 phosphorylation after poly(I·C) treatment
(Fig. 1C). It is important to note that truncation mutants may unintentionally affect
protein folding, and thus negative results using these mutants should be interpreted
with caution. As before, full-length pTRS1 blocked activation of PKR by poly(I·C)
treatment. However, pTRS1 lacking its amino-terminal 240 or 390 amino acids (pTRS1
240-795 or pTRS1 390-795, respectively), which contain the dsRNA binding domain, did
not inhibit PKR activation. Similarly, a pTRS1 mutant lacking the final 116 amino acids
FIG 1 Domains of pTRS1 necessary for PKR binding and inhibition. (A) Lysates from HEK293T cells
transfected with either a GFP or pTRS1 expression vector were treated with poly(I·C) to induce PKR
activation. Levels of phosphorylated PKR (T446) were measured by Western blotting. (B) Schematic showing
location of pTRS1 functional domains and pTRS1 truncation mutants (RBD, dsRNA binding domain; PBD,
PKR binding domain). Areas shaded gray are conserved between pTRS1 and pIRS1. (C) HEK293T cells were
transfected with GFP, full-length TRS1, or the indicated TRS1 mutants. Lysates were treated with poly(I·C),
and PKR phosphorylation (T446) was measured by Western blotting. (D) HEK293T cells were cotransfected
with Myc-tagged kinase-dead PKR (K296R) and either full-length TRS1 or the indicated TRS1 mutants. Cell
lysates were immunoprecipitated with anti-Myc (PKR) or IgG (specificity control) antibody. The presence of
pTRS1 in the immune complexes was determined by Western blotting. Representative results from one of
at least three independent experiments are shown for each panel.
Inhibition of PKR by HCMV pTRS1 Journal of Virology
March 2017 Volume 91 Issue 5 e01574-16 jvi.asm.org 3
(pTRS1 1-679), containing the PKR binding domain, also failed to antagonize PKR.
Curiously, the removal of an additional 180 amino acids from the C terminus (pTRS1
1-550) restored PKR inhibition, but further deletion (pTRS1 1-370) again led to an
inability to inhibit PKR activation.
Purified pTRS1 and PKR directly interact in vitro, and deletion or mutation of the PKR
binding domain ablates the ability of pTRS1 to inhibit PKR during HCMV infection (6, 7,
37). These results suggest that pTRS1 interaction with PKR is critical for PKR antagonism.
We therefore tested the ability of each pTRS1 mutant to bind PKR in transfected cells
(Fig. 1D). Cells were transfected with vectors expressing pTRS1 mutants together with
kinase-dead PKR (K296R), and the presence of pTRS1 in PKR-specific immune complexes
was determined by Western blotting. Only full-length pTRS1 bound to PKR. None of the
pTRS1 truncation mutants copurified with PKR, even pTRS1 240-795 and pTRS1 390-
795, which both contain the previously described PKR binding domain. Interestingly,
pTRS1 1-550 inhibited PKR activation (Fig. 1C) but did not bind PKR. These data suggest
that pTRS1 binding to PKR is sufficient, but not necessary, to prevent PKR activation by
dsRNA. However, as noted above, negative results in this assay should be interpreted
cautiously due to the potential effect of the truncations on protein folding.
TABLE 1 pTRS1 and PKR mutations and functional descriptionsa
Type of expression vector
and plasmid name Mutation Description Reference(s)
PKR expression vectors
PKR T446A T446A Mutation in activating phosphorylation site 23
PKR E375V E375V Confers resistance to inhibition by VV K3L 27
PKR A473T A473T
PKR D486V D486V
PKR T487A T487A Disrupts PKR phosphorylation of eIF2 3
PKR E490A F495R
PKR F495R E490A Mutation in conserved eIF2 G helix residue 4
PKR K296R Flag K296R Kinase-dead PKR with N-terminal Flag tag 3
PKR K296R Myc K296R Kinase dead PKR with N-terminal Myc tag
PKR GST-KD NA Doxycycline-inducible fusion of GST to the
PKR kinase domain (aa 259–551)
HRI-Myc NA HRI expression vector, C-terminal Myc tag This study
pTRS1 expression vectors
WT Full-length pTRS1 Binds both dsRNA and PKR 37, 39
pTRS1 1-370 C-terminal truncation mutant lacking final
425 aa
Contains RNA binding domain. Lacks PKR
binding domain
pTRS1 1-550 C-terminal truncation mutant lacking final
245 aa
Contains RNA binding domain. Lacks PKR
binding domain
pTRS1 1-679 C-terminal truncation mutant lacking final
116 aa
Contains RNA binding domain. Lacks PKR
binding domain
pTRS1 240-795 N-terminal truncation mutant lacking the first
239 aa
Lacks RNA binding domain. Contains PKR
binding domain
pTRS1 390-795 N-terminal truncation mutant lacking the first
299 aa
Lacks RNA binding domain. Contains PKR
binding domain
pTRS1triple Full-length pTRS1 containing point mutations
in the RNA binding domain (R121A, R124A,
and R125A)
Lacks ability to bind dsRNA 38
pTRS1mut1 Full-length pTRS1 containing point mutations
in the PKR binding domain (R658A, D660A,
D661A, and E662A)
Lacks ability to bind PKR 7
pTRS1mut1.triple Full-length pTRS1 containing point mutations
in the RNA (R121A, R124A, and R125A) and
PKR (R658A, D660A, D661A, and E662A)
binding domains
Lacks ability to bind both dsRNA and PKR 7, 38
pTRS1 1-550triple pTRS1 deletion mutant lacking final 245 aa
and containing point mutations in RNA
binding domain (R658A, D660A, D661A,
and E662A)
Lacks ability to bind both dsRNA and PKR 38, 39
pCW-pTRS1 NA Doxycycline-inducible full-length pTRS1 This study
aWT, wild type; aa, amino acids; VV, vaccinia virus; NA, not applicable.
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Relative role of dsRNA and PKR binding by pTRS1 in PKR antagonism. Amino
acids 84 to 246 of pTRS1 contain a noncanonical double-stranded RNA binding domain
(RBD) that allows purified pTRS1 to competitively inhibit the binding of purified PKR to
dsRNA (39). This function suggests that in addition to inhibiting PKR via a direct
interaction, pTRS1 may also inhibit PKR by preventing recognition of its dsRNA ligands
(38, 39). Consistent with this idea, the pTRS1 1-550 mutant, which lacks the PKR binding
domain, did not copurify with PKR but could still prevent PKR activation in response to
dsRNA treatment. To determine if pTRS1 1-550 inhibits PKR by binding to dsRNA, we
introduced three amino acid changes in the dsRBD of pTRS1 1-550 (pTRS1 1-550triple)
that prevent binding of purified pTRS1 to dsRNA (38). We then measured the ability of
this mutant to prevent poly(I·C)-induced PKR activation (Fig. 2A). pTRS1 1-550triple
could not prevent PKR activation in response to poly(I·C) treatment. Thus, in the context
of the truncated pTRS1 protein (pTRS1 1-550), RNA binding is necessary for PKR
antagonism.
In contrast, we found that pTRS1 could still inhibit PKR activation when the same
dsRBD mutations were introduced into full-length pTRS1 (pTRS1triple) (Fig. 2A). We
reasoned this could be due to pTRS1 binding to PKR through the previously defined
PKR binding domain (PBD). We therefore mutated amino acids in pTRS1 necessary for
binding to PKR (7) either alone (pTRS1mut1) or in combination with the dsRBD
mutations (pTRS1mut1.triple). Mutation of the pTRS1 PBD ablated both binding to PKR
(Fig. 2C) and the ability to inhibit poly(I·C)-induced PKR activation, even when the
dsRBD was intact (Fig. 2B), suggesting that the primary mechanism of PKR antagonism
by full-length pTRS1 is mediated through interactions with PKR. To further explore this
hypothesis, we tested if pTRS1 associated with PKR via an RNA intermediate (Fig. 2D).
Micrococcal nuclease treatment had no effect on pTRS1 binding to PKR. We also
FIG 2 PKR binding by full-length pTRS1 is necessary for inhibition of PKR activation. (A) Lysates from
HEK293T cells transfected with full-length TRS1 (WT) or the indicated TRS1 mutants. pTRS1 1-550 (1-550)
expresses only the first 550 amino acids of pTRS1. pTRS1triple (Triple) contains mutations that disrupt
dsRNA binding. pTRS1 1-550triple (1-550 Triple) expresses the 1-550 truncation mutant containing
mutations in the dsRNA binding domain. Lysates were incubated with poly(I·C) to activate PKR. PKR
phosphorylation (T446) was examined by Western blotting. (B) Same as panel A, except with different
TRS1 mutants. pTRS1mut1 (Mut1) contains mutations that disrupt PKR binding. (C) HEK293T cells were
transfected with Myc-tagged kinase-dead PKR (K296R) together with full-length TRS1 or the indicated
TRS1 mutants. pTRS1mut1.triple (Mut1-triple) contains point mutations in both the PKR and dsRNA
binding domains. Cell lysates were immunoprecipitated with anti-Myc (PKR) or IgG (specificity control)
antibody. The presence of pTRS1 in the immune complexes was determined by Western blotting. (D)
Same as panel C, except that lysates were treated with micrococcal nuclease prior to immunoprecipi-
tation. (E) MRC-5 fibroblasts were infected with HCMV at a multiplicity of infection (MOI) of 3 for 24 h.
The presence of PKR in pTRS1 or IE1 specific immune complexes was determined by Western blotting.
Representative results from one of at least three independent experiments are shown for each panel.
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demonstrated that pTRS1 interacts with PKR in HCMV-infected cells, which had not
been previously demonstrated (Fig. 2E). Together, these data suggest that pTRS1 has
two distinct mechanisms to inhibit PKR activation. In some circumstances, pTRS1 may
prevent PKR activation by sequestering dsRNA from PKR, independent of binding to
PKR. However, at least in this system, the primary mechanism of PKR inhibition by
full-length pTRS1 requires an RNA-independent interaction with PKR.
pTRS1 blocks PKR activation at a step after PKR dimerization. Binding to dsRNA
induces PKR dimerization, which is necessary for PKR activation (3, 51). We thus
hypothesized that pTRS1 might block PKR activation by preventing PKR dimerization.
To test this hypothesis, cells expressing pTRS1 were cotransfected with plasmids
encoding Myc- and Flag-tagged PKR K296R. Catalytically inactive PKR was used in these
experiments to limit toxicity. Poly(I·C) was added to cell lysates to induce PKR dimeriza-
tion, and the ability of Flag-tagged PKR to be copurified with Myc-tagged PKR was
measured by immunoprecipitation followed by Western blotting (Fig. 3). As expected,
Flag-tagged PKR was copurified with Myc-tagged PKR in the absence of pTRS1. Similar
amounts of Flag-PKR associated with Myc-PKR in the presence of pTRS1, suggesting
that pTRS1 does not affect PKR homodimer formation. In addition, we detected pTRS1
in the Myc-PKR immune complexes, suggesting that pTRS1 might bind to PKR dimers.
These data show that pTRS1 does not inhibit PKR activation by preventing PKR
dimerization and suggest that pTRS1 may in fact bind to PKR dimers.
To further test if pTRS1 prevents PKR activation at a step after dimerization, we
determined if pTRS1 could bind and inhibit a constitutively dimerized, active PKR. The
glutathione S-transferase (GST) protein constitutively forms dimers; replacing the
amino-terminal dsRBD of PKR with GST results in a constitutively dimerized, and thus
constitutively active, PKR kinase domain (GST-KD) (52). We asked if pTRS1 copurified
with GST-KD to determine if pTRS1 could bind the dimerized PKR kinase domain (Fig.
4A). As long-term expression of GST-KD is toxic, a doxycycline-inducible promoter was
used to regulate GST-KD expression. Wild-type pTRS1 was copurified with glutathione
resin from cells expressing GST-KD, while the PKR binding domain mutant (pTRS1mut1)
was not. We next determined if pTRS1 could inhibit the activity of a constitutively
dimerized PKR KD by measuring the effect of pTRS1 expression on GST-KD autophos-
phorylation (Fig. 4B). pTRS1 expression decreased GST-KD autophosphorylation com-
pared to those of GFP and pTRS1mut1 controls. Together, these results suggest that
pTRS1 binds and inhibits dimerized PKR and that pTRS1 binds PKR through an inter-
action with the PKR KD.
Amino acids in the PKR eIF2 contact site are important for pTRS1 binding.
Previous studies identified key amino acids in the G helix of the PKR kinase domain
that are necessary for binding of PKR to its substrate eIF2 (Fig. 5A) (3, 4). To determine
if pTRS1 interacted with the PKR eIF2 binding site, we examined the ability of pTRS1
FIG 3 pTRS1 does not prevent PKR dimerization. HEK293T cells expressing pTRS1 from an inducible
promoter (293T-pTRS1i) were cotransfected with Flag- and Myc-tagged PKR K296R expression vectors.
pTRS1 expression was induced with doxycycline treatment. Cell lysates were treated with poly(I·C), and
PKR was immunoprecipitated with anti-Myc antibody. The interaction of Flag- and Myc-tagged PKR was
examined by Western blotting. Representative results from one of at least three independent experi-
ments are shown.
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to bind and inhibit previously characterized PKR mutants with single amino acid
changes in the G helix (Table 1). Mutation of PKR residues Thr487 and Phe495 to
alanine and arginine (T487A and F495R, respectively) ablate PKR phosphorylation of
eIF2 but do not affect PKR catalytic activity or autophosphorylation (3). Two amino
acids within the PKR G helix, T487 and Glu490 (E490), are conserved in all eIF2
kinases (4). Therefore, we generated plasmids expressing PKR T487A, F495R, or E490A
mutants and measured their binding to pTRS1 (Fig. 5B). While pTRS1 was efficiently
copurified with wild-type PKR, very low levels of pTRS1 were recovered with the T487A
and E490A PKR mutants, which were visible only after overexposure of the blot. pTRS1
was copurified with the PKR F495R mutant, but at reduced levels. pTRS1 also main-
tained the ability to bind a PKR mutant in which the activating phosphorylation site had
FIG 4 pTRS1 binds and inhibits a constitutively active PKR kinase domain. (A) HEK293T cells were
cotransfected with a doxycycline-inducible GST-tagged PKR kinase domain (GST-KD) expression vector and
an expression vector encoding either pTRS1 or pTRS1mut1 (Mut1). GST-KD expression was induced with
doxycycline treatment. Glutathione resin was used to capture the GST-KD, and the copurification of pTRS1
or pTRS1mut1 was examined by Western blotting. (B) Cells were transfected as in panel A, with the addition
of cells cotransfected with a GFP expression vector and the GST-KD expression vector. GST-KD expression
was induced with doxycycline treatment, and levels of GST-KD autophosphorylation (T446) were deter-
mined by Western blotting. Representative results from one of at least three independent experiments are
shown for each panel.
FIG 5 pTRS1 interacts with the PKR kinase domain to prevent PKR autophosphorylation. (A) PyMOL image of the
PKR kinase domain and eIF2a (PDB code 2A1A). The PKR aG helix is represented in cyan. Amino acids required for
eIF2a binding are shown in magenta, while mutations that confer resistance to inhibition by K3L are shown in blue.
(B) 293T-pTRS1i cells were transfected with Myc-tagged PKR K296R or the indicated Myc-tagged PKR mutants.
pTRS1 expression was induced with doxycycline treatment before lysates were immunoprecipitated with anti-Myc
(PKR) or IgG (specificity control) antibody. The presence of pTRS1 in the immune complexes was determined by
Western blotting. (C) PKR-deficient HeLa cells (PKR KO) were transfected with the indicated PKR mutants together
with vectors expressing either GFP or TRS1. Cells were transfected with poly(I·C) to activate PKR and PKR
autophosphorylation (T446) was measured by Western blotting. (D and E) Same as panels B and C, except that cells
were transfected with the indicated PKR mutants. Representative results from one of at least three independent
experiments are shown for each panel.
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been mutated to alanine (T446A) (Fig. 5B). These data suggest that amino acids in the
PKR eIF2 contact site are important for pTRS1 binding and that PKR activation is not
necessary for its interaction with pTRS1.
We next tested the ability of pTRS1 to prevent activation of each of the above-
mentioned PKR mutants. pTRS1 and the PKR mutants were expressed in PKR-deficient
cells, and PKR autophosphorylation was measured after poly(I·C) transfection (Fig. 5C).
Consistent with previous results, poly(I·C) induced the autophosphorylation of each PKR
mutant in control cells expressing GFP, demonstrating that each PKR mutant was
catalytically active (3, 4, 27). Though the PKR F495 mutant was activated to lower levels
than wild-type PKR in control cells, pTRS1 prevented autophosphorylation of the PKR
F495R mutant. In contrast, the PKR T487A and E490A mutants were resistant to
inhibition by pTRS1, consistent with the inability of pTRS1 to bind these mutants. From
these data, we conclude that binding of pTRS1 to the PKR G helix is necessary for
inhibition of PKR activation.
The vaccinia virus PKR antagonist K3L also binds PKR at an eIF2 contact residue
within the G helix, Asp486 (D486). Recently, PKR mutants resistant to K3L binding and
inhibition were identified (Fig. 5A) (27). To determine if pTRS1 bound PKR in a manner
structurally similar to that of K3L, we tested the ability of pTRS1 to bind and inhibit
three PKR mutants (the E375V, A473T, and D486V mutants) that escape inhibition by
K3L (Fig. 5D). We found that pTRS1 efficiently bound both the PKR E375V and A473T
mutants but showed decreased binding to the PKR D486V mutant. pTRS1 prevented
autophosphorylation of the PKR E375V and A473T mutants and reduced autophos-
phorylation of the PKR D486V mutant (Fig. 5E). These data suggest that while pTRS1
and K3L interact with the same region of PKR, these interactions occur in a structurally
distinct manner.
pTRS1 inhibits PKR kinase activity. The inhibition of PKR autophosphorylation by
pTRS1 at a step after PKR dimerization suggested that pTRS1 might inhibit PKR kinase
activity. To test this hypothesis, we measured PKR kinase activity in the presence of
pTRS1 (Fig. 6). Cells were transfected with a Myc-PKR expression plasmid together with
plasmids expressing the control protein GFP, wild-type pTRS1, or pTRS1mut1, which
cannot bind PKR. We then measured PKR kinase activity in Myc-specific immune
complexes using a peptide from histone H2A as a substrate. The histone H2A peptide
has previously been shown to be a substrate for PKR in vitro (3). PKR kinase activity was
significantly lower in pTRS1-expressing cells than in control cells expressing GFP or cells
FIG 6 pTRS1 inhibits PKR kinase activity. HEK293T cells were transfected with the indicated expression
vectors (PKR K296R, kinase-dead PKR; Mut1, pTRS1 containing PKR binding domain mutations). PKR was
immunoprecipitated with anti-Myc antibody and resuspended in kinase buffer. The kinase reaction was
performed “on bead” as described in Materials and Methods, using histone H2A peptide as a substrate.
PKR kinase activity was measured using the ADP-Glo kinase assay. The amount of kinase activity is
normalized to the background activity associated with nonspecific (IgG) immunoprecipitates, which was
set to 1. Statistical significance was determined using an unpaired Student t test (n  3; *, P  0.05).
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expressing kinase-dead PKR K296R. The pTRS1mut1 protein did not inhibit PKR kinase
activity, consistent with its inability to bind PKR and prevent PKR autophosphorylation.
In fact, in some experiments slightly elevated PKR kinase activity was found in cells
expressing pTRS1mut1, though the difference was not statistically significant. Together
with the above-described data, these results suggest that pTRS1 binding to the PKR
kinase domain inhibits PKR kinase activity, preventing activating autophosphorylation
of PKR and subsequent phosphorylation of its substrate eIF2.
pTRS1 binds and inhibits an additional eIF2 kinase. Our results show that
pTRS1 binds and inhibits PKR through interactions with amino acids in the PKR eIF2
contact site. Interestingly, two of the amino acids in the PKR G helix important for
pTRS1 binding are conserved in other eIF2 kinases. To further test the hypothesis that
interaction with the PKR eIF2 contact site is critical for pTRS1 binding, we determined
if pTRS1 could also bind an additional eIF2 kinase, HRI. We found that HRI was
copurified with pTRS1 in transfected 293T cells (Fig. 7A) and in HCMV-infected fibro-
blasts (Fig. 7B). Treating cells with arsenite leads to an accumulation of reactive oxygen
species (ROS), which activates the HRI kinase, resulting in eIF2 phosphorylation (53).
To determine if pTRS1 could prevent HRI-dependent eIF2 phosphorylation, we mea-
sured eIF2 phosphorylation after arsenite treatment in PKR-deficient cells (Fig. 7C).
Arsenite induced a dose-dependent increase in eIF2 phosphorylation, which was
decreased in cells expressing pTRS1. This result is consistent with our previous study
showing that pTRS1 inhibits stress granule formation in PKR-deficient cells treated with
arsenite (6). As HRI activation does not require an interaction with dsRNA, these data
further confirm that pTRS1 can inhibit eIF2 kinases independent of its ability to bind
RNA. In addition, these data further support the conclusion that residues in the eIF2
contact site are critical for pTRS1 interaction with PKR and may mediate interactions
with additional eIF2 kinases.
DISCUSSION
In this study, we sought to examine the mechanism by which HCMV pTRS1 inhibits
the antiviral kinase PKR. Our results suggest that pTRS1 employs two mechanisms to
block PKR activation. In isolation, the amino-terminal 550 amino acids of pTRS1, which
contain the RNA binding domain, can prevent PKR activation independent of binding
to PKR (Fig. 1). However, in the context of full-length pTRS1, mutations that disrupt
pTRS1 RNA binding do not affect its ability to prevent PKR activation (Fig. 2). Rather,
binding of pTRS1 to PKR appears to be essential for PKR antagonism. pTRS1 did not
block PKR dimerization (Fig. 3) but instead could bind and inhibit a constitutively
dimerized PKR kinase domain (Fig. 4). pTRS1 binding to PKR inhibits PKR kinase activity
(Fig. 6) and is mediated through interactions with conserved amino acids in the PKR
FIG 7 pTRS1 binds HRI and limits its activation. (A) 293T-pTRS1i cells were transfected with Myc-tagged HRI,
and pTRS1 expression was induced with doxycycline. Lysates were immunoprecipitated with anti-Myc (PKR)
or control antibody (Tubulin), and the presence of HRI the immune complexes was determined by
Western blotting. (B) MRC-5 fibroblasts were infected with HCMV at an MOI of 3 for 72 h. The amount of
HRI that was copurified with pTRS1 specific immune complexes or with beads alone (control) was
determined by Western blotting. (C) PKR KO-pTRS1i cells were treated with doxycycline to induce pTRS1
expression and subsequently treated with increasing concentrations of arsenite (ARS) to activate HRI. Levels
of eIF2 phosphorylation were measured by Western blotting. The ratio of phosphorylated eF2 to total
eIF2 levels (P/total) was calculated by densitometry. Representative results from one of at least three
independent experiments are shown for each panel.
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eIF2 contact site. Mutation of these residues rendered PKR resistant to pTRS1 antag-
onism (Fig. 5). Consistent with this finding, pTRS1 interacted with an additional eIF2
kinase, HRI, and limited HRI activation in PKR-deficient cells (Fig. 7). Together, our data
suggest that inhibition of PKR kinase activity, mediated by pTRS1 binding to conserved
residues within the PKR eIF2 contact site, is the dominant mechanism of PKR antag-
onism.
Both pTRS1 and pIRS1 contain a noncanonical RNA binding domain in their con-
served N termini. Although the affinity of pTRS1 for dsRNA is lower than that of PKR, the
higher abundance of pTRS1 and pIRS1 in relation to PKR during infection may allow for
competition for dsRNA binding (38, 39). Our data show that in some contexts, dsRNA
binding by pTRS1 contributes to PKR antagonism. pTRS1 1-550 did not bind PKR (Fig.
1D) but maintained the ability to inhibit PKR activation in response to poly(I·C)
treatment (Fig. 1C). Mutations within pTRS1 1-550 that disrupt dsRNA binding (1-
550triple) ablated the ability of pTRS1 1-550 to inhibit PKR (Fig. 2A), suggesting that in
the context of the truncated protein, dsRNA binding is necessary for PKR inhibition.
Interestingly, this truncation mutant comprises the conserved region between pTRS1
and pIRS1, suggesting that dsRNA binding by both proteins may contribute to PKR
antagonism during infection, although the function of dsRNA binding by pTRS1/pIRS1
during infection has not been examined. It is also possible that pTRS1 1-550 has a
higher binding affinity for dsRNA than full-length pTRS1, allowing for efficient binding
and sequestration of poly(I·C) in vitro. Nevertheless, these data suggest that in some
contexts, dsRNA binding by pTRS1 contributes to PKR antagonism.
While dsRNA binding was necessary for the pTRS1 1-550 mutant to inhibit PKR, the
ability of full-length pTRS1 to bind dsRNA was dispensable for PKR antagonism (Fig. 2B).
Consistent with this result, pTRS1 binding to PKR was not dependent on an RNA
intermediate (Fig. 2D) and pTRS1 inhibited the activation of a constitutively active PKR
kinase domain lacking its dsRNA binding domains (Fig. 4B). Instead, we found that an
interaction between PKR and full-length pTRS1 was necessary for PKR antagonism (Fig.
2). Thus, at least in this system, pTRS1 binding to PKR, rather than competition for
dsRNA ligands, is the primary mechanism by which pTRS1 prevents PKR activation. This
is consistent with previous studies showing that the pTRS1 PKR binding domain is
necessary for PKR inhibition during HCMV infection in primary human fibroblasts (7, 35).
However, as discussed above, our results suggest that dsRNA binding by pTRS1 does
play a role in PKR inhibition. Previous studies have shown that a pTRS1 mutant
incapable of binding dsRNA (pTRS1triple) did not rescue replication of a vaccinia virus
lacking its PKR antagonist, even though pTRS1triple maintained the ability to bind PKR
(38). While dsRNA accumulates in HCMV-infected cells (18), the signals driving PKR
activation during HCMV infection are unknown. Perhaps these two functions of pTRS1,
binding to dsRNA and PKR, are most important for PKR inhibition in different settings
or in response to different PKR-activating signals.
We also identified the domain of PKR necessary for its association with pTRS1. Our
finding that pTRS1 could bind and inhibit a constitutively active PKR kinase domain
(GST-KD) suggested that an interaction between pTRS1 and the PKR kinase domain is
necessary for PKR antagonism (Fig. 4A and B). Using a series of previously described PKR
point mutants that retain PKR catalytic activity (3, 4, 27), we found that pTRS1 interacts
with specific amino acids in the G helix of the PKR kinase domain that are necessary
for binding to its substrate, eIF2 (Fig. 5). pTRS1 was not copurified with PKR mutants
containing G helix mutations (PKR T487A or E490A mutant) and weakly interacted
with an additional G helix mutant, the PKR D486V mutant (Fig. 5B and D). The loss of
binding correlated with a decrease in the ability of pTRS1 to inhibit activation of these
PKR mutants (Fig. 5C and E). The PKR T487A and E490A mutants were completely
resistant to inhibition by pTRS1, while the D486V mutant was partially resistant. In
contrast, mutations in PKR residues more distal to the eIF2 contact site (E375V and
A473T) had a minimal effect on pTRS1 binding, and pTRS1 prevented activation of both
mutants in response to poly(I·C) treatment (Fig. 5D and E). Thus, our data suggest that
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inhibition of PKR by pTRS1 requires an interaction with the eIF2 contact site in the PKR
kinase domain.
These results were reminiscent of PKR inhibition by the vaccinia virus K3L protein.
K3L binds the PKR G helix and functions as a PKR pseudosubstrate (26, 27, 54).
Mutation of PKR E375 or A473 to valine and threonine, respectively, confers resistance
of PKR to K3L inhibition (27). We found that pTRS1 bound both the E375 and A473 PKR
mutants (Fig. 5D) and prevented their autophosphorylation in response to poly(I·C)
treatment (Fig. 5E). These results are again consistent with a model in which pTRS1
binding mediates PKR antagonism. In addition, these data suggest that pTRS1 inhibi-
tion of PKR activation occurs in a manner structurally distinct from that of other viral
PKR antagonists.
In addition to a distinct binding modality, we found that pTRS1 also differs from K3L
in its mode of PKR inhibition. K3L does not inhibit PKR catalytic activity but rather
prevents phosphorylation of eIF2 by acting as a PKR pseudosubstrate (26, 54). Our
data show that pTRS1 binds PKR and inhibits PKR kinase activity (Fig. 6). Importantly,
the kinase assay used measures the conversion of ATP to AMP as a result of kinase
activity. In the presence of pTRS1, AMP accumulation is reduced, indicating a loss of
PKR catalytic activity. Thus, unlike K3L, pTRS1 does not act as a PKR pseudosubstrate
but rather inhibits PKR kinase activity toward the histone H2A substrate. Together,
these results suggest that pTRS1 binds the PKR kinase domain and inhibits its catalytic
activity.
When considered in sum, our data suggest that pTRS1 inhibits PKR activation and
subsequent eIF2 phosphorylation at multiple levels. In some scenarios, pTRS1 may
sequester dsRNA ligands to prevent PKR dimerization and activation. In addition, we
found that pTRS1 inhibits PKR at a step after dimerization through an interaction with
the G helix of the PKR kinase domain. pTRS1 binding to the kinase domain inhibits PKR
catalytic activity, thus preventing autophosphorylation of dimerized PKR and subse-
quent phosphorylation of eIF2. While not addressed herein, the fact that pTRS1 binds
to PKR residues necessary for its interaction with eIF2 suggests that pTRS1 could also
prevent eIF2 recognition by PKR. Thus, inhibition of PKR kinase activity by pTRS1
ensures that eIF2 is not phosphorylated, even when PKR has bound activating dsRNA
ligands.
As the two residues in PKR recognized by pTRS1 are conserved across all eIF2
kinases, we reasoned that pTRS1 might bind and inhibit additional eIF2 kinases. We
previously found that pTRS1 can prevent stress granule formation in response to
arsenite treatment in PKR-deficient cells, suggesting that pTRS1 has the ability to block
HRI-dependent eIF2 phosphorylation (53). In this study, we found that pTRS1 binds
HRI (Fig. 7A and B) and limits eIF2 phosphorylation in response to arsenite treatment
in PKR-deficient cells (Fig. 7C). These data further support the conclusion that residues
in the PKR G helix necessary for eIF2 binding are critical for interaction of pTRS1 with
PKR. In addition, these data suggest that pTRS1 could have a more general role in
suppressing cellular stress responses during HCMV infection, allowing for efficient
cellular and viral protein synthesis in the face of robust cellular stress induced by
infection.
MATERIALS AND METHODS
Cells and viruses. HEK293T cells and MRC-5 fibroblasts were cultured in Dulbecco’s modified Eagle
medium (Sigma) supplemented with 10% fetal bovine serum (Sigma) and 100 U/ml of penicillin-
streptomycin (Sigma) at 37°C and 5% CO2. PKR-deficient HeLa cells (PKR KO), HEK293T cells containing
an inducible TRS1 expression cassette (293T-pTRS1i), and PKR-deficient cells containing an inducible
TRS1 expression cassette (PKR KO-pTRS1i) were maintained in 1 g/ml of puromycin in normal growth
media. PKR-deficient HeLa cells have been previously described (35). The HCMV AD169inGFP strain was
used for all infections. This strain is derived from a bacterial artificial chromosome (BAC) and contains a
green fluorescent protein (GFP) reporter driven by the simian virus 40 (SV40) promoter.
Generation of recombinant plasmids. Vectors expressing full-length TRS1 or TRS1 truncation
mutants fused to a carboxyl-terminal 6His epitope were a kind gift from Adam Geballe (University
of Washington [39]). To generate full-length TRS1 containing arginine-to-alanine mutations that
disrupt dsRNA binding (R121A, R124A, and R125A [38]), the full-length TRS1 expression plasmid was
amplified with primers Triple F and Triple R (Table 2), and recircularized using Gibson cloning (New
Inhibition of PKR by HCMV pTRS1 Journal of Virology
March 2017 Volume 91 Issue 5 e01574-16 jvi.asm.org 11
TABLE 2 Primer and gBlock gene fragment sequencesa
Primer name Sequence (5= ¡ 3=)
Triple F GCGGCCATGGCCGCCTGGTCGCAGCGCGACGCGGGCAC
Triple R GACCAGGCGGCCATGGCCGCGCCCGTGCTGTTGGCCAGAA
Mut1 F CTTTGGCCCGGGCCGCCGCCGATTGGAAACCGCCACGTCTCCCTGGGGAAG
Mut1 R CAATCGGCGGCGGCCCGGGCCAAAGCACGTCCCAAACTGGCTTGGGGAGTC
PKRflag F TAAGCTTGGTACCGAGCTCGCCACCATGGACTACAAGGACGACGACGACAAGGCTGGTGATCTTTCAGCAGG
PKR R CGCGGGCCCTCTAGACTCGATCAACATGTGTGTCGTTCATTTT
PKRmyc F TAAGCTTGGTACCGAGCTCGCCACCATGGAACAAAAACTCATCTCAGAAGAGGATCTGGCTGGTGATCTTTCAGCAGG
PKR_E375V F AGGGACCTTGGTACAATGGATTGAAAAAAGAAGAGGCGAGAAAC
PKR_E375V R CAATCCATTGTACCAAGGTCCCTTTATCACAGAATTCCATTTGG
PKR_A473T F GTGGACCTCTACACTTTGGGGCTAATTCTTGCTGAACTTCTTC
PKR_A473T R CCCAAAGTGTAGAGGTCCACTTCCTTTCCATAGTCTTGCG
PKR_T446A F GATGGAAAGCGAGCAAGGAGTAAGGGAACTTTGCGATACA
PKR_T446A R CTCCTTGCTCGCTTTCCATCATTTTTCAGAGATGTTACAAG
PKR_D486V F CTTCATGTATGTGTCACTGCTTTTGAAACATCAAAGTT
PKR_D486V R AGCAGTGACACATACATGAAGAAGTTCAGCAAGAATTAGCC
PKR_T487A F GTATGTGACGCTGCTTTTGAAACATCAAAGTTTTTCACAGACCTACGG
PKR_T487A R GTTTCAAAAGCAGCGTCACATACATGAAGAAGTTCAGCAAGAATTAGCC
PKR_E490A F GACACTGCTTTTGCAACATCAAAGTTTTTCACAGACCTACGGGATG
PKR_E490A R CTTTGATGTTGCAAAAGCAGTGTCACATACATGAAGAAGTTCAG
PKR_F495R F CAAAGTTTCGCACAGACCTACGGGATGGCATCATCTCAG
PKR_F495R R TAGGTCTGTGCGAAACTTTGATGTTTCAAAAGCAGTGTCAC
GST_pCW F CAGATCGCCTGGAGAATTGGCTAGCgccaccATGTCCCCTATACTAGGTTATTGG
GST R TGGAGGATGGTCGCCACCAC
KD_GST F GTGGTGGCGACCATCCTCCAACTGTGGACAAGAGGTTTGG
KD_GST_pCW R CGCAACCCCAACCCCGGATCCTCAACATGTGTGTCGTTCATTTTTC
TRS1ind F CAGATCGCCTGGAGAATTGGCTAGCgccaccATGGCCCAGCGCAACGGCAT
TRS1ind R CGCAACCCCAACCCCGGATCCTTATTGAGCATTGTAATGGT
HRImyc F TAAGCTTGGTACCGAGCTCGgccgccaccATGGAACAAAAACTCATCTCAGAAGAGGATCTGCAGGGGGGCAACTCCGGGGTC
HRImyc R CGCGGGCCCTCTAGACTCGATCACAATCCCACGCCCCCATCCTTTC
PKR gBlock TAAGCTTGGTACCGAGCTCGCCACCATGGCTGGTGATCTTTCAGCAGGTTTCTTCATGGAGGAACTTAATACATACCGTCAGA
AGCAGGGAGTAGTACTTAAATATCAAGAACTGCCTAATTCAGGACCTCCACATGATAGGAGGTTTACATTTCAAGTTATAA
TAGATGGAAGAGAATTTCCAGAAGGTGAAGGTAGATCAAAGAAGGAAGCAAAAAATGCCGCAGCCAAATTAGCTGTTGA
GATACTTAATAAGGAAAAGAAGGCAGTTAGTCCTTTATTATTGACAACAACGAATTCTTCAGAAGGATTATCCATGGGGAA
TTACATAGGCCTTATCAATAGAATTGCCCAGAAGAAAAGACTAACTGTAAATTATGAACAGTGTGCATCGGGGGTGCATG
GGCCAGAAGGATTTCATTATAAATGCAAAATGGGACAGAAAGAATATAGTATTGGTACAGGTTCTACTAAACAGGAAGCA
AAACAATTGGCCGCTAAACTTGCATATCTTCAGATATTATCAGAAGAAACCTCAGTGAAATCTGACTACCTGTCCTCTGGTT
CTTTTGCTACTACGTGTGAGTCCCAAAGCAACTCTTTAGTGACCAGCACACTCGCTTCTGAATCATCATCTGAAGGTGACTT
CTCAGCAGATACATCAGAGATAAATTCTAACAGTGACAGTTTAAACAGTTCTTCGTTGCTTATGAATGGTCTCAGAAATAAT
CAAAGGAAGGCAAAAAGATCTTTGGCACCCAGATTTGACCTTCCTGACATGAAAGAAACAAAGTATACTGTGGACAAGA
GGTTTGGCATGGATTTTAAAGAAATAGAATTAATTGGCTCAGGTGGATTTGGCCAAGTTTTCAAAGCAAAACACAGAATTG
ACGGAAAGACTTACGTTATTAAACGTGTTAAATATAATAACGAGAAGGCGGAGCGTGAAGTAAAAGCATTGGCAAAACTT
GATCATGTAAATATTGTTCACTACAATGGCTGTTGGGATGGATTTGATTATGATCCTGAGACCAGTGATGATTCTCTTGAGA
GCAGTGATTATGATCCTGAGAACAGCAAAAATAGTTCAAGGTCAAAGACTAAGTGCCTTTTCATCCAAATGGAATTCTGTG
ATAAAGGGACCTTGGAACAATGGATTGAAAAAAGAAGAGGCGAGAAACTAGACAAAGTTTTGGCTTTGGAACTCTTTGAA
CAAATAACAAAAGGGGTGGATTATATACATTCAAAAAAATTAATTCATAGAGATCTTAAGCCAAGTAATATATTCTTAGTA
GATACAAAACAAGTAAAGATTGGAGACTTTGGACTTGTAACATCTCTGAAAAATGATGGAAAGCGAACAAGGAGTAAGG
GAACTTTGCGATACATGAGCCCAGAACAGATTTCTTCGCAAGACTATGGAAAGGAAGTGGACCTCTACGCTTTGGGGCTA
ATTCTTGCTGAACTTCTTCATGTATGTGACACTGCTTTTGAAACATCAAAGTTTTTCACAGACCTACGGGATGGCATCATCTC
AGATATATTTGATAAAAAAGAAAAAACTCTTCTACAGAAATTACTCTCAAAGAAACCTGAGGATCGACCTAACACATCTGA
AATACTAAGGACCTTGACTGTGTGGAAGAAAAGCCCAGAGAAAAATGAACGACACACATGTTCGAGTCTAGAGGGCCCGCG
PKR K296R gBlock TAAGCTTGGTACCGAGCTCGCCACCATGGCTGGTGATCTTTCAGCAGGTTTCTTCATGGAGGAACTTAATACATACCGTCAGA
AGCAGGGAGTAGTACTTAAATATCAAGAACTGCCTAATTCAGGACCTCCACATGATAGGAGGTTTACATTTCAAGTTATAA
TAGATGGAAGAGAATTTCCAGAAGGTGAAGGTAGATCAAAGAAGGAAGCAAAAAATGCCGCAGCCAAATTAGCTGTTGA
GATACTTAATAAGGAAAAGAAGGCAGTTAGTCCTTTATTATTGACAACAACGAATTCTTCAGAAGGATTATCCATGGGGAA
TTACATAGGCCTTATCAATAGAATTGCCCAGAAGAAAAGACTAACTGTAAATTATGAACAGTGTGCATCGGGGGTGCATG
GGCCAGAAGGATTTCATTATAAATGCAAAATGGGACAGAAAGAATATAGTATTGGTACAGGTTCTACTAAACAGGAAGCA
AAACAATTGGCCGCTAAACTTGCATATCTTCAGATATTATCAGAAGAAACCTCAGTGAAATCTGACTACCTGTCCTCTGGT
TCTTTTGCTACTACGTGTGAGTCCCAAAGCAACTCTTTAGTGACCAGCACACTCGCTTCTGAATCATCATCTGAAGGTGACT
TCTCAGCAGATACATCAGAGATAAATTCTAACAGTGACAGTTTAAACAGTTCTTCGTTGCTTATGAATGGTCTCAGAAATAATC
AAAGGAAGGCAAAAAGATCTTTGGCACCCAGATTTGACCTTCCTGACATGAAAGAAACAAAGTATACTGTGGACAAGAGGTT
TGGCATGGATTTTAAAGAAATAGAATTAATTGGCTCAGGTGGATTTGGCCAAGTTTTCAAAGCAAAACACAGAATTGACGGA
AAGACTTACGTTATTCGGCGTGTTAAATATAATAACGAGAAGGCGGAGCGTGAAGTAAAAGCATTGGCAAAACTTGATCATGT
AAATATTGTTCACTACAATGGCTGTTGGGATGGATTTGATTATGATCCTGAGACCAGTGATGATTCTCTTGAGAGCAGTGATTAT
GATCCTGAGAACAGCAAAAATAGTTCAAGGTCAAAGACTAAGTGCCTTTTCATCCAAATGGAATTCTGTGATAAAGGGAC
CTTGGAACAATGGATTGAAAAAAGAAGAGGCGAGAAACTAGACAAAGTTTTGGCTTTGGAACTCTTTGAACAAATAACA
AAAGGGGTGGATTATATACATTCAAAAAAATTAATTCATAGAGATCTTAAGCCAAGTAATATATTCTTAGTAGATACAAAA
CAAGTAAAGATTGGAGACTTTGGACTTGTAACATCTCTGAAAAATGATGGAAAGCGAACAAGGAGTAAGGGAACTTTGC
GATACATGAGCCCAGAACAGATTTCTTCGCAAGACTATGGAAAGGAAGTGGACCTCTACGCTTTGGGGCTAATTCTTGCTG
AACTTCTTCATGTATGTGACACTGCTTTTGAAACATCAAAGTTTTTCACAGACCTACGGGATGGCATCATCTCAGATATATT
TGATAAAAAAGAAAAAACTCTTCTACAGAAATTACTCTCAAAGAAACCTGAGGATCGACCTAACACATCTGAAATACTAA
GGACCTTGACTGTGTGGAAGAAAAGCCCAGAGAAAAATGAACGACACACATGTTCGAGTCTAGAGGGCCCGCG
aLowercase sequences represent Kozak sequences.
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England BioLabs [NEB]). The R121A, R124A, and R125A point mutations were introduced into the
1-550 TRS1 expression vector, as described above, using the pcDNATRS1 1-550 plasmid as a
template. Point mutations within the pTRS1 PKR binding domain that disrupt PKR binding (R658A,
D660A D,661A, and E662A [7]) were incorporated into full-length TRS1 and TRS1triple using primers
Mut1 F and Mut1 R (Table 1) followed by recircularization using a Gibson reaction (New England
BioLabs), in which a mixture of DNA exonuclease, DNA polymerase, and DNA ligase anneal
overlapping cDNA ends into a contiguous double-stranded DNA molecule. The portion of each clone
containing the TRS1 open reading frame (ORF) was sequenced to ensure the absence of unintended
mutations.
The human protein kinase R (PKR) ORF containing homology arms to the pcDNA3.1 V5 His expression
vector was ordered as a gBlock gene fragment (IDT; Table 2). The pcDNA3.1 vector was digested with
BamHI and XhoI, and the full-length PKR ORF was inserted using a Gibson cloning reaction according to
the manufacturer’s directions. The kinase-dead PKR (K296R) ORF containing homology arms to the
pcDNA3.1 expression vector was also ordered as a gBlock gene fragment (Table 2) and introduced into
pcDNA3.1 by Gibson cloning as described above. A Flag epitope was fused to the N terminus of PKR
K296R by amplification of the PKR ORF with primers PKRflag F and PKR R (Table 2) followed by Gibson
cloning into the pcDNA3.1 vector digested with BamHI and XhoI as described above. An N-terminal
Myc tag was added to both wild-type PKR and PKR K296R as described above using the primers
PKRmyc F and PKR R. The following point mutations were introduced into PKR: E375V, T446A, A473T,
D486V, T487A, E490A, and F495R using primer pairs PKR_E375V F and PKR_E375V R, PKR_A446T F
and PKR_A446T R, PKR_T473A F and PKR_T473A R, PKR_D486V F and PKR_D486V R, PKR_T487A F and
PKR_T487A R, PKR_E490A F and PKR_E490A R, and PKR_F495R F and PKR_F495R R, respectively. All
primer sequences are listed in Table 2. The full-length PKR expression plasmid was amplified from
the Myc-tagged wild-type PKR and the Myc-tagged PKR K296R expression plasmids with the
above-listed primer pairs. The PCR products were then gel extracted and circularized using Gibson
cloning. For each PKR mutant, the portion of each vector containing the PKR ORF was sequenced to
confirm the absence of additional mutations.
The PKR kinase domain (KD) fused to glutathione S-transferase (GST) was created by first amplifying
GST from pET-41 b() using primers GST-pCW F and GST R (Table 2). The PKR KD (amino acids 259 to
551) was then amplified from the full-length PKR expression vector using primers KDGST F and
KDGSTpCW R (Table 2). The plasmid pCW-Cas9 (Addgene; number 50661) was digested with NheI and
BamHI to remove the Cas9 open reading frame. The GST ORF and PKR KD were then cloned into the
digested pCW vector using a three-part Gibson reaction. Full-length TRS1 was introduced into the pCW
plasmid by amplifying the TRS1 ORF using primers TRS1ind F and TRS1ind R (Table 2), followed by Gibson
assembly into pCW-Cas9 previously digested with NheI and BamHI. Sanger sequencing was used to
confirm the absence of unintended mutations.
The heme-regulated inhibitor (HRI) ORF was amplified from the pJP1563 vector (DNASU; number
38827) using primers HRImyc F and HRImyc R (Table 2). The HRI ORF was then cloned into the pcDNA3.1
vector digested with BamHI and XhoI via Gibson reaction. The complete HRI ORF was sequenced to
ensure the absence of unintended mutations.
Production of lentivirus stocks and pTRS1-inducible cell lines. Lentivirus stocks were generated
by transfecting HEK293T cells with the pCW TRS1 expression plasmid (described above) and lentivirus
packaging mix (Sigma) using polyethylenimine (PEI; Polysciences). The medium was collected at 48 h and
72 h after transfection and clarified by passage through a 0.22-m filter. The virus was then stored at
80°C until use. 293T-pTRS1i and PKR KO-pTRS1i cells were generated by transduction with the pCW
TRS1 lentivirus in the presence of 8 g/ml of Polybrene. After bulk selection in 1 g/ml of puromycin for
48 h, clonal cell lines were isolated by limiting dilution in media containing puromycin. Clonal cell lines
were assayed for minimal basal expression of pTRS1 and maximal induction of pTRS1 expression after
treatment with 1 g/ml of doxycycline by Western blotting.
PKR and HRI activation assays. The ability of pTRS1 or pTRS1 mutants to inhibit PKR was measured
in HEK293T cells. Cells were transfected with 1 g of either a GFP or TRS1 expression plasmid using PEI
and harvested at 36 h after transfection. Cells were washed with phosphate-buffered saline (PBS),
pelleted, and lysed in 120 l of PKR lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.5% NP-40, 10%
glycerol, and 1 mM EDTA with protease and phosphatase inhibitors [Roche]) on ice for 15 min. Insoluble
debris was removed by centrifugation at 21,000  g for 10 min at 4°C. Unless otherwise indicated, 1
mg/ml of poly(I·C) (LMW; Invivogen) was added to 100 l of supernatant for 30 min at 30°C to activate
PKR. To examine PKR KD activation, HEK293T cells were transfected with 500 ng of GST-KD expression
plasmid together with 500 ng of either GFP, TRS1 or TRS1mut1 expression plasmid for 36 h. Doxycycline
(1 g/ml) was added to cells overnight prior to harvest to induce GST-KD expression. Cells were washed
once with PBS, pelleted, and stored at 80°C until processed. To measure activation of PKR mutants in
PKR KO cells, PKR KO-pTRS1i cells were cotransfected with 500 ng of PKR expression plasmid and 500 ng
of either GFP or TRS1 expression plasmid. Twenty hours after DNA transfection, cells were transfected
with 20 g of poly(I·C) using Lipofectamine 2000 (Thermo Fisher) for 4 h. Cells were washed once in PBS,
pelleted, and stored at 80°C until processed.
PKR KO-pTRS1i cells were used to measure the effect of pTRS1 on arsenite-induced HRI activation.
Cells were treated overnight with doxycycline (1 g/ml) to induce pTRS1 expression. The next day, cells
were treated with 0.05, 0.25, or 0.5 mM sodium arsenite (Sigma) for 2 h to activate HRI (53). Cells were
then washed once with PBS, pelleted, and stored at 80°C until processed.
Analysis of protein expression. Unless otherwise stated, cells were lysed in RIPA buffer (50 mM
Tris-HCl [pH 7.4], 150 mM NaCl, 1% NP-40, 0.25% deoxycholate, and 1 mM EDTA containing protease and
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phosphatase inhibitors; Roche). Protein concentration was determined using a Bradford assay. Equal
amounts of protein were resolved on 10% SDS-PAGE gels, transferred to nitrocellulose membranes
(Amersham), and blocked in 5% nonfat milk in TBS-T (50 mM Tris [pH 7.4], 150 mM NaCl, 0.1% Tween
20) for 1 h at room temperature (RT) or overnight at 4°C. For mouse monoclonal antibodies,
membranes were incubated with primary antibodies for either 1 h at RT or overnight at 4°C in 1%
bovine serum albumin (BSA) in TBS-T. For rabbit polyclonal antibodies, membranes were blocked as
described above and incubated at 4°C overnight in 5% BSA in TBS-T, with the exception of the
anti-His antibody, which was diluted in 1% BSA in TBST-T. Membranes were incubated in appropriate
secondary antibodies (KPL) at a 1:10,000 dilution in 1% BSA in TBS-T for 1 h at RT. A modified
protocol was used for total and phosphorylated eIF2 blots. Membranes probed for total eIF2 were
blocked and incubated in primary antibody as described above and then incubated in secondary
antibody (1:10,000) in 5% milk in TBS-T for 1 h at RT before being developed. Membranes probed
for phospho-eIF2 (Ser51) were blocked in 5% BSA in TBS-T overnight at 4°C prior to an overnight
incubation in primary antibody at 4°C. Membranes were then incubated in secondary antibody
(1:10,000) in 1% BSA in TBS-T for 1 h at RT. Antibodies against the following were used: pTRS1 (1:100
[43]), His (1:1,000; CST; number 2365S), total PKR (1:1,000; Santa Cruz; sc-707), phospho-PKR (Thr446)
(1:1,000; Abcam; ab32036), Myc (1:1,000; CST; number 2276S), Flag (1:1,000; Sigma; F3165), eIF2
(1:1,000; CST; number 9722S), phospho-eIF2 (Ser51) (1:1,000; CST; number 3398S), HRI (1:1,000;
Abcam; ab28530), and tubulin (1:20,000; Sigma; T6199).
Immunoprecipitation. HEK293T cells were transfected with 5 g of the desired plasmid for a total
of 36 h. Where indicated, doxycycline (1 g/ml) was added 18 h prior to harvest to induce pTRS1
expression. Cells were lysed in 1 ml of PKR lysis buffer for 15 min on ice. Insoluble debris was removed
by centrifugation for 10 min at 21,000  g at 4°C. One hundred microliters of protein A/G Sepharose
beads (Santa Cruz) in PKR lysis buffer (20-l packed-bead volume) was added to each sample and
nutated at 4°C for 30 min to preclear the lysate. Where indicated, 2,000 U of micrococcal nuclease (NEB)
and 5 l of 0.5 M CaCl2 were added to each sample prior to the preclearing step and incubated at 37°C
for 30 min to digest nucleic acid species. The beads were then removed and the lysate was transferred
to a new tube containing 1 g of the desired antibody, or 1 g of either mouse IgG or tubulin antibody
as a negative control. Samples were nutated with antibody at 4°C for 4 h, after which 100 l of protein
A/G beads in PKR lysis buffer (20-l packed-bead volume) was added to each sample. For the anti-TRS1
immunoprecipitation, antibodies were preconjugated to protein A/G beads overnight before addition to
sample lysates. Samples were nutated for 90 min after the addition of the beads. The beads were
collected by brief centrifugation and washed three times with 1 ml of PKR lysis buffer before addition of
30 l of 1 sample buffer (0.1 M Tris-HCl [pH 6.8], 6% glycerol, 2% SDS, 0.1 M dithiothreitol [DTT], 0.002%
bromophenol blue). The samples were boiled at 95°C for 10 min, briefly centrifuged at 21,000  g, and
stored at 20°C prior to analysis by Western blotting.
For the glutathione Sepharose pulldown, HEK293T cells were cotransfected with 2.5 g of inducible
GST-PKR kinase domain (GST-KD) expression plasmid and 2.5 g of either TRS1 or TRS1mut1 expression
plasmid for 36 h. GST-KD expression was induced by addition of 1 g/ml of doxycycline 18 h before
harvest. Upon harvest, cells were washed once with PBS, pelleted, and lysed in 500 l of wash buffer (20
mM HEPES [pH 7.0], 100 mM NaCl, 1 mM DTT, 1% glycerol) for 15 min on ice. Insoluble debris was
removed by centrifugation at 21,000  g for 10 min at 4°C. One hundred microliters of washed
glutathione Sepharose 4B (GE) (15-l packed-Sepharose volume) was added to each sample. Samples
were nutated at RT for 1 h and then washed three times with 1 ml of wash buffer. Thirty microliters of
1 sample buffer was added to the beads, after which samples were boiled, briefly centrifuged, and
stored at 20°C until analysis by Western blotting.
PKR kinase assay. HEK293T cells were transfected with 5 g of the desired plasmids for 36 h. For
cotransfections, 2.5 g of each plasmid was transfected. Immunoprecipitation using anti-Myc or mouse
IgG was performed as described above. After a washing in PKR lysis buffer, beads were resuspended in
25 l of 1 kinase reaction buffer (40 mM Tris [pH 7.5], 20 mM MgCl2, 0.1 mg/ml of BSA, 500 M ATP
[Promega]) containing 7.5 g of histone H2A peptide (NEB) as a substrate. The kinase reaction was run
for 30 min at RT. The ADP-Glo kinase assay (Promega) was then used to determine PKR kinase activity.
Briefly, 25 l of ADP-Glo reagent was added to each kinase reaction and incubated at RT for 40 min. Fifty
microliters of kinase detection reagent was added to each sample and incubated at RT for an additional
40 min, after which the luminescence of each sample was read using a luminometer (Molecular Devices).
Fold change in luminescence compared to the IgG control immunoprecipitation was calculated, and
statistical significance was determined using an unpaired Student t test.
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